Allergy Testing

Nearly 60% of asthmatic adults and 90% of asthmatic children have allergy triggers that may lead to full-blown respiratory distress.1,2

Why Test With ImmunoCAP?

Between 80-85% of asthma and upper respiratory diseases are managed by primary care clinicians.3 With ImmunoCAP in-vitro test, the presence of IgE antibodies to allergens in the blood can quickly be determined.

Test Benefits

  • Confirms or excludes the presence of allergies 
  • Identifies specific allergens to avoid 
  • Allergy panels are specifically designed for our Pacific Northwest region 
  • Potentially eliminates unnecessary medications since 65% of patients taking non-sedating antihistamines are not allergic.4

Access region-specific allergy requisitions at this link​​.


References

 

  1. Allen-Ramey, et al. Sensitization to common allergens in adults with asthma. J Am Board Fam Pract 2005;18:434-439.
  2. For NIH updated guidelines and recommendations for asthma control, see Expert Panel Report
  3. Guidelines for the Diagnosis and Management of Asthma, NIH, 2007. 3. R. A. Wood, W. Phipatanakul, R.G. Hamilton and P.A. Eggleston. J Allergy Clin Immunol; May 1999, Vol 103, No. 5, Part 1.4. Spector SL, executive ed. Dialogues in Redefining Rhinitis. Office of Continuing Medical Education, UCLA School of Medicine: Health Learning Systems, Inc; 1996;1(1,4):1- 16.
  4. Szeinbach SL, Williams PB, Muntendam P, O’Connor R. Identification of allergic disease among users of antihistamines. J Manag Care Pharm. 2004;10(3) 234-238.

​ ​